A sugar substitute widely used in chewing gum, toothpaste, and various sugar-free consumer products is facing intense scientific scrutiny. In a landmark study presented at the European Society of Cardiology (ESC) Congress in Munich, researchers reported a strong correlation between elevated blood levels of xylitol and a substantially higher risk of major adverse cardiovascular events, including heart attacks, strokes, and cardiovascular-related deaths.
The study, which tracked 17,710 individuals, represents the largest population-based analysis to date evaluating the long-term cardiovascular outcomes associated with xylitol. The findings have ignited a fresh debate over the safety of sugar alcohols, which are heavily marketed as healthier alternatives to traditional sugar amidst global efforts to combat obesity and diabetes.
Scaling Up the Evidence: The 2026 Cohort Findings
The research, presented by Dr. Marco Witkowski of the Charité University Hospital in Berlin, analyzed data from two major prospective observational cohorts: the Canadian Longitudinal Study on Aging and the EPIC-Norfolk study. By dividing participants based on their baseline blood xylitol concentrations, researchers compared the clinical outcomes of individuals in the highest and lowest percentiles.
Over a six-year observation window, participants with the highest measured xylitol levels exhibited a 57% higher risk of experiencing a major adverse cardiovascular event. This association remained statistically significant even after adjusting for traditional risk factors, including age, biological sex, smoking status, diabetes, hypertension, and lipid profiles. Notably, when the follow-up period was extended over a span of up to 30 years, an elevated risk remained measurable at approximately 18%.
The researchers also documented a distinct dose-response pattern, wherein the incidence of cardiovascular events climbed progressively alongside rising blood concentrations of the sweetener. This trend suggests that the association is not merely anomalous but scales directly with exposure levels.
Biological Pathways and Clotting Mechanics
The 2026 population study builds directly on biological mechanisms identified in a peer-reviewed paper published in the European Heart Journal in 2024. That earlier research, which examined a discovery cohort of 1,157 people and a validation cohort of 2,149 individuals, sought to understand how xylitol interacts with human blood chemistry.
Through laboratory and animal models, investigators found that xylitol significantly enhances platelet reactivity and increases the potential for thrombosis (blood clotting). In a small-scale human intervention trial involving ten healthy volunteers, consuming a xylitol-sweetened beverage led to a rapid spike in blood xylitol levels alongside a measurable increase in multiple markers of platelet responsiveness.
“In previous studies, we showed that xylitol can enhance the ability of platelets to form clots,” Dr. Witkowski explained during his presentation in Munich. “We also found that high blood levels of xylitol were linked to cardiovascular events in high-risk individuals over a three-year period. Artificial sweeteners are consumed by people who think they are healthier than sugar, and they are generally regarded as safe by regulatory agencies, which warrants closer examination.”
The Commercial Footprint: Gum, Toothpaste, and Spreads
Xylitol belongs to the polyol family of sugar alcohols, which also includes erythritol, sorbitol, mannitol, and maltitol. Chemically distinct from high-intensity sweeteners like aspartame or sucralose, polyols are favored by food and oral-care manufacturers because they provide bulk and sweetness with fewer calories than sucrose, while actively resisting the bacteria that cause tooth decay.
This dental benefit has made xylitol a staple in the global confectionery market. Brands like Trident (produced by Perfetti Van Melle) incorporate xylitol alongside other sugar alcohols in various formulations. Other manufacturers, such as The PUR Company, market products sweetened with 100% birch- and beech-derived xylitol. Beyond confectionery, the sweetener is commonly used in oral hygiene products, such as Colgate-Palmolive’s Tom’s of Maine Whole Care toothpaste, and in low-calorie jams and sweet spreads.
The economic stakes surrounding these ingredients are vast. In the United States alone, sugarless gum sales generated approximately $3 billion for the 12 months ending in mid-2025, accounting for the vast majority of the overall $3.4 billion gum market. Globally, the sugar-free chewing gum market was valued at an estimated $9.04 billion in 2025, with some broader industry projections exceeding $13 billion.
Regulatory Stances and Global Anomalies
Currently, major food safety authorities, including the U.S. Food and Drug Administration (FDA) and European regulators, classify xylitol and other sugar alcohols as “Generally Recognized as Safe” (GRAS) or permit their use under broad food additive guidelines. For instance, the FDA noted during a 2023 review of erythritol—another polyol that faced similar cardiovascular scrutiny—that existing evidence did not establish a definitive causal relationship between its consumption and adverse cardiac events.
Interestingly, regulatory frameworks for products like chewing gum vary wildly across jurisdictions. Singapore, for example, maintains a strict national prohibition on the sale and import of standard chewing gum, carrying fines of up to S$2,000 for violations. However, Singaporean customs and health regulations make explicit exceptions for registered therapeutic and dental products. Gums containing 12% to 36% xylitol, combined with specific active ingredients like calcium lactate, are legally permitted as medical or dental health products.
The Scientific Consensus: Association vs. Causation
Despite the striking nature of the 57% risk increase observed over six years, public health experts and the study authors emphasize that these findings are observational. They show a correlation but do not prove that consuming products containing xylitol directly causes heart attacks or strokes.
Because human metabolic pathways produce small amounts of xylitol endogenously, elevated blood levels can sometimes reflect underlying metabolic differences rather than dietary intake alone. Consequently, the scientific community is calling for rigorous, long-term clinical trials to isolate dietary xylitol consumption from endogenous production and definitively assess its safety profile.
For consumers, navigating ingredient labels remains complex. Products labeled “sugar-free” or “no sugar added” frequently rely on complex blends of multiple polyols and artificial sweeteners, making it difficult to gauge actual exposure levels without careful inspection of ingredient lists.